West Pharmaceutical Services, Inc.

NYSE
WST
Stock
Yield per half year: -30.26%
Dividend yield: 0.3106%
Sector: Healthcare

Company Analysis West Pharmaceutical Services, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Current debt level 8.3% is below 100% and has decreased over 5 years from 14.07%.
  • The company's current efficiency (ROE=17.71%) is higher than the sector average (ROE=-83.36%)

Disadvantages

  • Price (205.59 $) is higher than fair price (83.3 $)
  • Dividends (0.3106%) are below the sector average (1.26%).
  • The stock's return over the last year (-28.72%) is lower than the sector average (-21.87%).

Similar companies

PerkinElmer

AbbVie

PFIZER

Johnson & Johnson

2. Share price and performance

2.1. Share price

2.3. Market efficiency

West Pharmaceutical Services, Inc. Healthcare Index
7 days 6.6% -35.8% 0.9%
90 days -2.9% -21% 8.8%
1 year -28.7% -21.9% 12%

WST vs Sector: West Pharmaceutical Services, Inc. has significantly underperformed the "Healthcare" sector by -6.85% over the past year.

WST vs Market: West Pharmaceutical Services, Inc. has significantly underperformed the market by -40.75% over the past year.

Stable price: WST is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: WST with weekly volatility of -0.5522% over the past year.

3. Summary of the report

3.1. General

P/E: 49.19
P/S: 8.38

3.2. Revenue

EPS 6.69
ROE 17.71%
ROA 13.19%
ROIC 28.73%
Ebitda margin 25.71%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (205.59 $) is higher than the fair price (83.3 $).

Price is higher than fair: The current price (205.59 $) is 59.5% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (49.19) is lower than that of the sector as a whole (53.14).

P/E vs Market: The company's P/E (49.19) is lower than that of the market as a whole (62.2).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (9.03) is lower than that of the sector as a whole (10.86).

P/BV vs Market: The company's P/BV (9.03) is lower than that of the market as a whole (20.84).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (8.38) is higher than that of the sector as a whole (4.06).

P/S vs Market: The company's P/S indicator (8.38) is lower than that of the market as a whole (16.02).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (32.33) is higher than that of the sector as a whole (16.98).

EV/Ebitda vs Market: The company's EV/Ebitda (32.33) is higher than that of the market as a whole (27.16).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 8.46% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (8.46%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-10.32%).

5.4. ROE

ROE vs Sector: The company's ROE (17.71%) is higher than that of the sector as a whole (-83.36%).

ROE vs Market: The company's ROE (17.71%) is lower than that of the market as a whole (43.08%).

5.5. ROA

ROA vs Sector: The company's ROA (13.19%) is higher than that of the sector as a whole (6.41%).

ROA vs Market: The company's ROA (13.19%) is lower than that of the market as a whole (23.27%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (28.73%) is higher than that of the sector as a whole (15.68%).

ROIC vs Market: The company's ROIC (28.73%) is higher than that of the market as a whole (9.29%).

6. Finance

6.1. Assets and debt

Debt level: (8.3%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 14.07% to 8.3%.

Debt Covering: The debt is covered by 61.36% from net profit.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0.3106% is below the average for the sector '1.26%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 0.3106% has been steadily paid over the past 7 years, DSI=0.86.

Weak dividend growth: The company's dividend yield 0.3106% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (12%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum West Pharmaceutical Services, Inc.

9.3. Comments